<DOC>
	<DOCNO>NCT00654706</DOCNO>
	<brief_summary>The objective study explore neurocognitive efficacy Sertindole versus comparator patient schizophrenia use MCCB .</brief_summary>
	<brief_title>Efficacy Study Exploring Effects Cognition Sertindole Versus Comparator Patients With Schizophrenia</brief_title>
	<detailed_description>Sertindole atypical antipsychotic approve European Union ( EU ) use patient schizophrenia intolerant least one antipsychotic agent . During clinical development sertindole find effective treatment schizophrenia first-generation antipsychotic haloperidol second-generation antipsychotic risperidone . Sertindole generally well tolerated benign side-effect profile , include absence sedation , effect plasma prolactin level , moderate weight gain , anticholinergic-mediated cognitive impairment low rate extrapyramidal symptom ( EPS ) . Sertindole show prolong QT interval contraindicate patient prolonged QT interval patient receive drug know significantly prolong QT interval . The study design provide data neurocognitive property sertindole versus quetiapine patient schizophrenia . Efficacy cognitive impairment assess patient stable phase illness , predefined maximum level symptom allow include study . Prior antipsychotic medication withdrawn ( down-tapered ) patient randomly assign one study drug . Cognitive deficiency important feature schizophrenia correlate strongly functional impairment . Improving functional outcome schizophrenia high priority result initiation program call Measurement Treatment Research Improve Cognition Schizophrenia ( MATRICS ) lead development neuropsychological test battery , MCCB use study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Sertindole</mesh_term>
	<criteria>Primary diagnosis schizophrenia Man woman , age 18 55 year Current Axis I primary psychiatric diagnosis schizophrenia Not previously receive antipsychotic drug schizophrenia Acute exacerbation require hospitalisation within last 3 month Clinically significant extrapyramidal symptom Clinically significant cardiovascular disease , congestive heart failure , cardiac hypertrophy , arrhythmia bradycardia Congenital long QT syndrome family history disease , know acquire QT interval prolongation Significant ECG abnormalities Hypokalaemia hypomagnesaemia In concurrent treatment drug inhibit P450 enzyme system CYP3A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognition</keyword>
	<keyword>MATRICS Consensus Cognitive Battery</keyword>
</DOC>